



Review

Post-infectious group A streptococcal autoimmune syndromes and the heart



William John Martin ^{a,b,*}, Andrew C. Steer ^{c,d}, Pierre Robert Smeesters ^{c,d}, Joanne Keeble ^{a,b}, Michael Inouye ^e, Jonathan Carapetis ^f, Ian P. Wicks ^{a,b,g,*}

^a Inflammation Division, Water and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia

^b Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia

^c Centre for International Child Health, Department of Pediatrics, University of Melbourne and Murdoch Childrens Research Institute, Parkville, VIC 3052, Australia

^d Group A Streptococcus Laboratory, Murdoch Childrens Research Institute, Parkville, VIC 3052, Australia

^e Medical Systems Biology, Department of Pathology and Department of Microbiology and Immunology, University of Melbourne, VIC 3010, Australia

^f Telethon Kids Institute, University of Western Australia, WA, Australia

^g Rheumatology Unit, Royal Melbourne Hospital, Parkville, VIC 3052, Australia

ARTICLE INFO

Article history:

Received 2 April 2015

Accepted 10 April 2015

Available online 17 April 2015

Keywords:

Group A streptococcus
Acute rheumatic fever
Rheumatic heart disease
Glomerulonephritis
PANDAS
Autoimmunity

ABSTRACT

There is a pressing need to reduce the high global disease burden of rheumatic heart disease (RHD) and its harbinger, acute rheumatic fever (ARF). ARF is a classical example of an autoimmune syndrome and is of particular immunological interest because it follows a known antecedent infection with group A streptococcus (GAS). However, the poorly understood immunopathology of these post-infectious diseases means that, compared to much progress in other immune-mediated diseases, we still lack useful biomarkers, new therapies or an effective vaccine in ARF and RHD. Here, we summarise recent literature on the complex interaction between GAS and the human host that culminates in ARF and the subsequent development of RHD. We contrast ARF with other post-infectious streptococcal immune syndromes – post-streptococcal glomerulonephritis (PSGN) and the still controversial paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), in order to highlight the potential significance of variations in the host immune response to GAS. We discuss a model for the pathogenesis of ARF and RHD in terms of current immunological concepts and the potential for application of in depth “omics” technologies to these ancient scourges.

© 2015 Elsevier B.V. All rights reserved.

Contents

1. Introduction	711
2. Post-streptococcal immune mediated syndromes	712
2.1. Acute rheumatic fever (ARF) and rheumatic heart disease (RHD)	712
2.2. Post-streptococcal glomerulonephritis (PSGN)	712
2.3. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)	712
3. Genetics of host susceptibility to post-streptococcal immune syndromes	713
4. Bacterial factors that contribute to post-streptococcal immune syndromes	713
5. Host responses in post-streptococcal immune syndromes	716
5.1. Complement and immune complex activation	716
5.2. Molecular mimicry in ARF and RHD	717
5.3. Cellular immunological responses in ARF and RHD	718
5.4. Cytokines in ARF and RHD	718
5.5. A vaccine against GAS	719
6. Where to next in understanding post-streptococcal immune syndromes?	719
7. Immunopathogenesis of post-streptococcal immune syndromes: shared or specific mechanisms?	719
Take-home messages	720

* Corresponding authors at: Inflammation Division, Water and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia. Tel.: +61 9345 2555.
E-mail addresses: martin@wehi.edu.au (W.J. Martin), wicks@wehi.edu.au (I.P. Wicks).

Acknowledgements 720
 References 721

1. Introduction

Human infections with *Streptococcus pyogenes* (group A streptococcus, GAS) constitute a major, worldwide health problem, with up to 700 million cases annually [1]. GAS is an anaerobic, Gram-positive coccus and its only known reservoir is in humans. The oropharynx and skin are the primary colonization sites for GAS and around 12% of apparently normal individuals harbour GAS as a commensal organism in these locations [2].

GAS has a long history with human disease. Intriguingly, it can cause both infectious and post-infectious, immune-mediated diseases. The former includes non-invasive infections, such as pharyngitis and impetigo; invasive infections, such as pneumonia, septic arthritis and necrotising fasciitis; and toxin-mediated syndromes, such as toxic shock syndrome and scarlet fever. Immune syndromes following GAS infection include acute rheumatic fever (ARF), rheumatic heart disease (RHD), post-streptococcal glomerulonephritis (PSGN) and possibly, paediatric autoimmune neuropsychiatric disorders associated with




Fig. 1. Target organs of post-streptococcal immune syndromes.

Download English Version:

<https://daneshyari.com/en/article/3341413>

Download Persian Version:

<https://daneshyari.com/article/3341413>

[Daneshyari.com](https://daneshyari.com)